Table 4 Treatment rate ratios for chemotherapy & radiotherapy (CTRT) within 6 months of diagnosis of lung, oesophageal, pancreatic and stomach cancers in 2013–2014, from a fully adjusted multivariable model with sex, age at diagnosis, deprivation, ethnicity and Charlson comorbidity index, stratified by cancer site

From: Sociodemographic variation in the use of chemotherapy and radiotherapy in patients with stage IV lung, oesophageal, stomach and pancreatic cancer: evidence from population-based data in England during 2013–2014

 

NSCLC

SCLC

Oesophagus

Stomach

Pancreas

 

%a

TRR (95% CI)

%a

TRR (95% CI)

%a

TRR (95% CI)

%a

TRR (95% CI)

%a

TRR (95% CI)

Sex

  Male

12

Ref

31

Ref

9

Ref

4

Ref

1

Ref

  Female

12

0.96 (0.90, 1.03)

33

1.00 (0.90, 1.10)

6

0.82 (0.63, 1.07)

3

0.63 (0.42, 0.95)

1

1.06 (0.71, 1.57)

  p for heterogeneityb

 

0.22

 

0.93

 

0.15

 

0.03

 

0.79

Age at cancer diagnosis

  <50

29

1.52 (1.33, 1.74)

50

1.31 (1.03, 1.66)

10

0.87 (0.52, 1.44)

9

1.69 (1.00, 2.85)

3

1.77 (0.86, 3.63)

  50 – 59

25

1.36 (1.25, 1.49)

47

1.26 (1.10, 1.43)

14

1.37 (1.03, 1.82)

5

1.04 (0.60, 1.78)

3

2.07 (1.24, 3.48)

  60 – 69

18

Ref

39

Ref

10

Ref

5

Ref

2

Ref

  70 – 79

9

0.53 (0.49, 0.58)

25

0.59 (0.53, 0.67)

7

0.75 (0.57, 0.98)

3

0.56 (0.35, 0.88)

1

0.77 (0.45, 1.32)

  80+

2

0.11 (0.10, 0.13)

11

0.28 (0.22, 0.35)

2

0.24 (0.14, 0.40)

1

0.26 (0.13, 0.51)

0

0.28 (0.12, 0.68)

  p for heterogeneityb

 

<0.0001

 

<0.0001

 

<0.0001

 

<0.0001

 

<0.0001

Charlson comorbidity index

  0

13

Ref

34

Ref

9

Ref

4

Ref

2

Ref

  1

8

0.73 (0.65, 0.83)

28

0.88 (0.75, 1.04)

9

1.27 (0.88, 1.83)

3

0.93 (0.50, 1.74)

2

1.19 (0.66, 2.14)

  2

7

0.71 (0.60, 0.84)

27

0.92 (0.74, 1.14)

5

0.76 (0.41, 1.44)

3

1.06 (0.49, 2.30)

1

0.66 (0.21, 2.11)

  3+

3

0.35 (0.27, 0.45)

15

0.50 (0.36, 0.70)

4

0.71 (0.33, 1.51)

2

0.80 (0.25, 2.55)

0

0.27 (0.04, 1.92)

  p for heterogeneityb

 

<0.0001

 

0.0004

 

0.33

 

0.98

 

0.45

Deprivation quintile

  1: least deprived

13

Ref

32

Ref

11

Ref

4

Ref

2

Ref

  2

13

0.98 (0.88, 1.10)

32

0.91 (0.76, 1.09)

9

0.86 (0.63, 1.19)

3

0.93 (0.52, 1.66)

2

1.00 (0.56, 1.77)

  3

11

0.86 (0.77, 0.96)

35

1.03 (0.87, 1.23)

7

0.70 (0.50, 0.98)

4

1.16 (0.67, 2.01)

1

0.71 (0.38, 1.33)

  4

11

0.82 (0.74, 0.92)

31

0.87 (0.73, 1.03)

8

0.71 (0.51, 0.99)

4

0.96 (0.55, 1.69)

1

1.00 (0.55, 1.82)

  5: most deprived

11

0.77 (0.69, 0.85)

30

0.81 (0.68, 0.96)

7

0.61 (0.43, 0.87)

3

0.90 (0.50, 1.62)

1

0.84 (0.44, 1.63)

  p for heterogeneityb

 

<0.0001

 

0.009

 

0.04

 

0.91

 

0.79

Ethnicity

  White

12

Ref

32

Ref

8

Ref

4

Ref

1

Ref

  Non-white

18

1.16 (1.01, 1.33)

31

0.83 (0.59, 1.15)

10

1.24 (0.64, 2.43)

5

1.08 (0.59, 1.97)

1

0.39 (0.12, 1.26)

  Unknown

8

0.67 (0.55, 0.83)

21

0.73 (0.51, 1.05)

3

0.39 (0.16, 0.95)

2

0.53 (0.13, 2.16)

1

0.46 (0.11, 1.88)

  p for heterogeneityb

 

0.0001

 

0.13

 

0.09

 

0.65

 

0.17

  1. CI confidence interval, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, TRR treatment rate ratio.
  2. a Proportion of patients recorded to receive treatment in each category.
  3. b Performed jointly across all categories of each variable, using a post-estimation Wald test
Back to article page